



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

April 24, 2019

Saiid Zarrabian  
President and Chief Executive Officer  
DelMar Pharmaceuticals, Inc.  
Suite 720-999 West Broadway  
Vancouver, BC, Canada V5Z 1K5

**Re: DelMar Pharmaceuticals, Inc.  
Registration Statement on Form S-1  
Filed April 18, 2019  
File No. 333-230929**

Dear Mr. Zarrabian:

We have limited our review of your registration statement to those issues we have addressed in our comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments.

Registration Statement on Form S-1 filed on April 18, 2019

Cover page

1. We note your disclosure that the rights offering will expire on or about a certain date, and that you may extend the rights offering for additional periods in your sole discretion. Please revise your disclosure to provide an expiration date for the rights offering that is not indefinite. Refer to Item 501(b)(8)(iii) of Regulation S-K.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Saiid Zarrabian  
DelMar Pharmaceuticals, Inc.  
April 24, 2019  
Page 2

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Christine Westbrook at 202-551-5019 or Joe McCann at 202-551-6262 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Steven M. Skolnick, Esq.